Astellas v. Sandoz: XOSPATA Gilteritinib — Consent Injunction Blocks Generic Entry
Astellas Pharma and its U.S. affiliates sued Sandoz over six patents covering gilteritinib tablets (XOSPATA), a targeted therapy for acute myeloid leukemia. The case closed after 722 days when Sandoz accepted a consent injunction barring generic launch for the life of all six asserted patents — a significant win for Astellas without a full trial.
Consent Injunction Secures XOSPATA Exclusivity Without Trial
Astellas Pharma, Inc., Astellas Pharma US, Inc., and Astellas US, LLC filed suit on March 2, 2023 in the U.S. District Court for the District of New Jersey against Sandoz, Inc., triggered by Sandoz’s ANDA No. 217683 — a generic gilteritinib tablet application seeking to enter the market occupied by Astellas’s XOSPATA (gilteritinib) 40 mg tablets. Six patents were asserted: US10786500B2, US11938130B2, US11938131B2, US11938132B2, US11938133B2, and US11944620B2, collectively covering the composition, formulation, and use of gilteritinib.
The case resolved on February 21, 2025 through a stipulated order agreed by both parties. All claims, defenses, and counterclaims were dismissed without prejudice — meaning no merits ruling was issued. Critically, the order includes a consent injunction: Sandoz is enjoined from manufacturing, selling, offering for sale, importing, or using its generic gilteritinib product in the United States for the life of all six asserted patents, including any patent term extensions and pediatric exclusivity periods, absent a license from Astellas or a final court finding of invalidity or unenforceability.
At 722 days, the case ran for nearly two years before settling via consent order — consistent with ANDA litigation patterns where defendants assess litigation risk before investing in a full trial. The absence of fee-shifting and the without-prejudice dismissal technically preserve future litigation rights, but the injunction functionally secures Astellas’s market position for the patent lifecycle. What remains unknown from the public record is whether any licensing discussions are ongoing or whether Sandoz received any commercial concessions not reflected in the court order.
Filing to Dismissed without Prejudice in 722 days
722 days — longer than median ANDA patent case resolution in NJ District Court
Consent injunction and without-prejudice dismissal: what the order means for both parties
Dismissed without prejudice — but an injunction does the heavy lifting
A dismissal without prejudice normally preserves both parties’ rights to re-litigate. Here, however, the stipulated order pairs that dismissal with a binding consent injunction against Sandoz. This structure is common in ANDA settlements: it formally ends the litigation without a merits ruling while functionally preventing generic entry for the patent term. The without-prejudice label does not diminish the operational force of the injunction.
Consent order — no merits rulingAstellas secures full-patent-life exclusivity without trial risk
Astellas obtains the commercial equivalent of a trial win: Sandoz is barred from launching its generic for the life of all six patents, including any term extensions and pediatric exclusivity. Astellas avoids the cost and uncertainty of a bench trial while maintaining XOSPATA’s exclusivity window. The only exit for Sandoz is a separate court finding of invalidity or unenforceability — a high bar requiring fresh litigation.
Exclusivity preserved through patent lifeSandoz accepts injunction — generic launch effectively deferred
By consenting to the injunction, Sandoz foregoes near-term generic launch of gilteritinib under ANDA 217683. The without-prejudice dismissal technically keeps invalidity arguments alive for a future proceeding (e.g., IPR or a new declaratory judgment action), but in practice this outcome suggests Sandoz assessed the litigation risk and chose a negotiated exit. No costs were awarded against Sandoz, which may reflect a balanced negotiation.
Generic launch deferredSix-patent wall around gilteritinib raises the barrier for all generic entrants
The consent order signals the strength of Astellas’s patent estate around gilteritinib. Any ANDA filer for gilteritinib must contend with six overlapping patents, including composition and formulation claims. The injunction’s scope — covering manufacturing, sale, import, and use — is broad. For the AML treatment market, this outcome suggests continued branded exclusivity for XOSPATA and a higher litigation risk premium for any generic developer evaluating entry.
Strong multi-patent barrier maintainedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Astellas Pharma, Inc. | Company | Global pharmaceutical company — holder of US10786500B2 and five related gilteritinib patentsSearch in Eureka ↗ |
| Co-Plaintiff | Astellas Pharma US, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Astellas US, LLC | Company | Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Generic pharmaceutical company — ANDA 217683 filer for gilteritinib 40 mg tabletsSearch in Eureka ↗ |
| Co-Defendant | PHV Elizabeth M. Flanagan | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Hector Daniel Ruiz | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jason Albert Leonard | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jayita Guhaniyogi | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jessica K. Formichella | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Selena Miriam Ellis | Attorney | Counsel for Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | DEMANT | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Mcdermott, Will & Emery, LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’reilly Falanga, LLP | Law Firm | Representing Astellas Pharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Kristine L. Butler | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | William Murtha | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Hill Wallack LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order is notable for pairing a without-prejudice dismissal — which carries no merits weight — with a substantive consent injunction binding Sandoz across all commercial activities relating to ANDA 217683. The injunction’s carve-out (invalidity or unenforceability found by a court from which no appeal can be taken) sets an extremely high threshold for Sandoz to resume generic development. The express waiver of appeal rights by both parties and the court’s retained jurisdiction for enforcement purposes signals that this order is intended to function as a durable resolution, not a temporary truce.
US10786500B2 and five related patents — gilteritinib tablet compositions and formulations
The six asserted patents — US10786500B2, US11938130B2, US11938131B2, US11938132B2, US11938133B2, and US11944620B2 — collectively protect the composition, formulation, and therapeutic application of gilteritinib, the active ingredient in Astellas’s XOSPATA. Gilteritinib is a FLT3/AXL inhibitor approved for adult patients with relapsed or refractory AML harbouring FLT3 mutations. The ‘500 patent, with the earliest application date (US15/741377), likely anchors the core composition claims, while the ‘130–’133 and ‘620 series (all filed on US18/316xxx applications) suggest continuation or divisional patents expanding formulation and method coverage.
Strategically, the six-patent cluster around gilteritinib represents a classic layered pharmaceutical patent portfolio designed to maximise the exclusivity window and complicate generic ANDA challenges. Each patent requires independent validity analysis, and collectively they cover different angles of attack — making it expensive and risky for a generic challenger to clear all six. For the oncology sector, where targeted therapies command premium pricing and small-molecule exclusivity is commercially critical, this portfolio architecture is a benchmark for how innovator companies should structure IP protection around high-value cancer treatments.
Should you run an FTO against US10786500B2 and the gilteritinib patent family?
Any organisation developing a generic or biosimilar form of gilteritinib, a next-generation FLT3 inhibitor for AML, or any tablet formulation incorporating gilteritinib as an active pharmaceutical ingredient should treat this six-patent family as a priority FTO target. The consent injunction entered in this case confirms that Astellas is actively enforcing these patents against ANDA filers. The scope of the ‘500 and continuation patents likely extends beyond the specific ANDA product to cover a broad range of gilteritinib compositions and dosage forms.
PatSnap Eureka’s FTO Search Agent allows R&D and regulatory teams to map claim scope across all six patents simultaneously, identify prosecution history estoppel, model patent term extensions, and flag any continuation or divisional applications still pending. Given the multi-patent layering here, a standard single-patent FTO is insufficient — Eureka’s portfolio-level FTO workflow can surface claim overlaps and identify the narrowest design-around paths across the entire gilteritinib patent estate.
Run a freedom-to-operate analysis on US11938133B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: gilteritinib and oncology small-molecule formulations
Cases involving Hatch-Waxman ANDA challenges to oncology small-molecule formulation patents in the District of New Jersey, with consent injunction or dismissal outcomes.
What this case signals for the oncology and ANDA patent litigation landscape
Astellas’s six-patent layering strategy and consent injunction outcome offer a blueprint for branded pharmaceutical exclusivity defence in Hatch-Waxman litigation.
Multi-patent ANDA strategies significantly raise generic entry barriers
Astellas asserted six patents covering different aspects of gilteritinib — composition, formulation, and method. This layered approach forces generic challengers to invalidate every asserted patent to launch, dramatically increasing litigation cost and risk. Branded pharma companies should consider analogous portfolio structures around high-value oncology assets.
Consent injunctions offer branded pharma a low-risk resolution pathway
By securing a consent injunction without a merits ruling, Astellas avoids the risk of an adverse validity finding that could affect its entire patent estate. Patent counsel advising innovator companies should evaluate consent order structures early in ANDA litigation — particularly where multiple patents can be bundled into a single injunction.
Astellas v Sandoz — key questions answered
The case was dismissed without prejudice on February 21, 2025 via a stipulated consent order. Critically, the order also enjoins Sandoz from manufacturing, selling, or importing its generic gilteritinib product (ANDA 217683) for the life of all six asserted patents, including any term extensions and pediatric exclusivities, absent a licence from Astellas or a final court invalidity ruling.
Astellas asserted six patents: US10786500B2, US11938130B2, US11938131B2, US11938132B2, US11938133B2, and US11944620B2. These patents collectively cover gilteritinib tablet compositions, formulations, and related pharmaceutical applications underpinning XOSPATA (gilteritinib) 40 mg tablets.
A dismissal without prejudice means no merits ruling was issued and either party technically retains the right to bring future proceedings on the same claims. In this case, however, the practical effect of the consent injunction — which blocks Sandoz’s generic launch for the patent lifetime — makes the dismissal functionally equivalent to an Astellas win at the district court level, without the risk of an adverse validity finding.
The consent order’s injunction carve-out permits Sandoz to resume generic commercialisation only if all asserted claims are found invalid or unenforceable by a court decision from which no further appeal is possible. This suggests Sandoz could pursue IPR proceedings at the USPTO PTAB or a new declaratory judgment action. However, both parties expressly waived the right to appeal or seek relief from the consent order itself.
The injunction explicitly extends to patent term extensions (PTEs) and pediatric exclusivity periods. This is commercially significant because gilteritinib’s effective market exclusivity window may extend beyond the nominal patent expiry date. Generic developers and market access analysts projecting gilteritinib generic entry timelines must account for these additional exclusivity layers when modelling competitive entry.
PatSnap Eureka searches patents and litigation data to answer instantly.